Navigation Links
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Date:4/4/2017

MOSCOW, April 4, 2017 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection. 180 subjects have been enrolled in 20 centers in Russia and Germany.

Maxwell Biotech Venture Fund Logo
Maxwell Biotech Venture Fund Logo

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b)

"We are pleased to participate in the MYR 202 trial and look forward to results of this world's largest study in this severe unmet medical need," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR's Clinical Advisory Board.

"We are thankful for the enthusiastic collaboration of the participating centers, which has allowed us to meet the recruitment goals within the planed period," commented Dr. Dmitry Popov, Managing Partner of Maxwell Biotech Fund. "The interim results of MYR 202 will be available by the end of 2017."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

About Hepatera 

The main activity of Hepatera Ltd. is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is developed by the company in cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany. Myr GmbH is received investments from Maxwell Biotech Venture Fund and High-Tech Gründerfonds (HTGF).

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The Fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.


'/>"/>
SOURCE Maxwell Biotech Venture Fund
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
2. Separation Systems for Commercial Biotechnology
3. Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia
4. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
5. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
6. On World Tuberculosis Day 2017, American/Russian biotech partnership announces positive trial results for a new treatment of TB
7. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
8. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
9. Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
10. Three Day Biotechnology for the Non-Biotechnologist Course (London, United Kingdom - September 27-28-29, 2017) - Research and Markets
11. Festo Introduces at Interphex a New Family of Sanitary/Automated Ball, Angle Seat, and Pinch Valves for the Pharma and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... powder activated carbon (PAC)-based materials do not have negative short- or long-term effects ... site contaminated with polychlorinated biphenyls (PCBs) located at the Puget Sound Naval Shipyard ...
(Date:6/27/2017)... JOHNSTON, Iowa (PRWEB) , ... June 27, 2017 ... ... a technology license agreement whereby DuPont gains exclusive rights to the ERS patent ... plants. ERS was formed to commercialize the foundational intellectual property (IP) of the ...
(Date:6/26/2017)... ... 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett Thompson. ... business development and ensuring quality customer experience. , Brett brings to Third ... technical, marketing and sales roles. “Brett’s background working with customers and eye for market ...
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were elected to the University ... 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President for ... Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. Holveck and ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
Breaking Biology News(10 mins):